Norethindrone-ethinyl estradiol various microgram combinations — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Contraception (Oral)

• Levonorgestrel-ethinyl estradiol combinations

What Norethindrone-ethinyl estradiol various microgram combinations is approved for (FDA label)

WERA™ Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT ® System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. 9 Lactational Amenorrhea Method: LAM is highly effective, temporary method of contraception. 10 Source: Trussell J, Contraceptive efficacy.

Source: Read the full FDA label on DailyMed. Label effective date: April 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Norethindrone-ethinyl estradiol various microgram combinations (FDA label)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination oral contraceptives, including WERA TM , should not be used by women who are over 35 years of age and smoke.

Source: FDA prescribing information (DailyMed). Set ID: 638e4f36-1a27-4220-8ec9-3fa9d9b36c11. SPL document ID: 1f26d981-43da-4b0e-bee1-7d195254fb77. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Norethindrone-ethinyl estradiol various microgram combinations (FDA label)

Post Marketing Experience: Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 2). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use.

Source: FDA prescribing information (DailyMed). Set ID: 638e4f36-1a27-4220-8ec9-3fa9d9b36c11. SPL document ID: 1f26d981-43da-4b0e-bee1-7d195254fb77. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Norethindrone-ethinyl estradiol various microgram combinations (FDA label)

Oral contraceptives should not be used in women who currently have the following conditions: ● Thrombophlebitis or thromboembolic disorders ● A past history of deep vein thrombophlebitis or thromboembolic disorders ● Known thrombophilic conditions ● Cerebral vascular or coronary artery disease (current or history) ● Valvular heart disease with complications ● Persistent blood pressure values of ≥160 mm Hg systolic or ≥100 mg Hg diastolic 96 ● Diabetes with vascular involvement ● Headaches with focal neurological symptoms ● Major surgery with prolonged immobilization ● Current diagnosis of, or history of, breast cancer, which may be hormone sensitive ● Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia ● Undiagnosed abnormal genital bleeding ● Cholestatic jaundice of pregnancy or jaundice with prior pill use ● Acute or chronic hepatocellular disease with abnormal liver function ● Hepatic adenomas or carcinomas ● Known or suspected pregnancy ● Hypersensitivity to any component

Source: FDA prescribing information (DailyMed). Set ID: 638e4f36-1a27-4220-8ec9-3fa9d9b36c11. SPL document ID: 1f26d981-43da-4b0e-bee1-7d195254fb77. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.